Beyond ocrelizumab in primary progressive multiple sclerosis

被引：0

作者：

Williams, Thomas ^{[1
]}

Chataway, Jeremy ^{[1
,2
]}

机构：

[1] UCL, Fac Brain Sci, UCL Queen Sq Inst Neurol, Queen Sq Multiple Sclerosis Ctr,Dept Neuroinflamm, London, England

[2] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England

来源：

NATURE REVIEWS NEUROLOGY | 2022年 / 18卷 / 11期

基金：

英国医学研究理事会;

关键词：

THERAPY;

D O I：

10.1038/s41582-022-00724-8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Currently, the anti-CD20 monoclonal antibody ocrelizumab is the only approved treatment for primary progressive multiple sclerosis (PPMS). However, a new study suggests that other immunomodulatory disease-modifying therapies that are often used to treat relapsing forms of multiple sclerosis could be effective in people with PPMS who have evidence of active inflammatory disease.

引用

页码：641 / 642

页数：2

共 50 条

[1] Beyond ocrelizumab in primary progressive multiple sclerosis
Thomas Williams
Jeremy Chataway
[J]. Nature Reviews Neurology, 2022, 18 : 641 - 642
[2] Ocrelizumab for primary progressive multiple sclerosis
Adler, Ai
Knight, H.
[J]. LANCET NEUROLOGY, 2019, 18 (09): : 816 - 817
[3] Ocrelizumab for primary progressive multiple sclerosis
Montalban X
Hauser SL
Kappos L
[J]. 中华物理医学与康复杂志, 2017, (03) : 174 - 174
[4] Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis
Deisenhammer, Florian
Auer, Michael
Hegen, Harald
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17): : 1693 - 1694
[5] Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis REPLY
Hauser, Stephen L.
Belachew, Shibeshih
Kappos, Ludwig
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17): : 1694 - 1694
[6] Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X.
Hauser, S. L.
Kappos, L.
Arnold, D. L.
Bar-Or, A.
Comi, G.
de Seze, J.
Giovannoni, G.
Hartung, H. -P.
Hemmer, B.
Lublin, F.
Rammohan, K. W.
Selmaj, K.
Traboulsee, A.
Sauter, A.
Masterman, D.
Fontoura, P.
Belachew, S.
Garren, H.
Mairon, N.
Chin, P.
Wolinsky, J. S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 209 - 220
[7] Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser, Stephen L.
Kappos, Ludwig
Montalban, Xavier
Craveiro, Licinio
Chognot, Cathy
Hughes, Richard
Koendgen, Harold
Pasquarelli, Noemi
Pradhan, Ashish
Prajapati, Kalpesh
Wolinsky, Jerry S.
[J]. NEUROLOGY, 2021, 97 (16) : E1546 - E1559
[8] Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis
Hartung, H. -P.
Arnold, D. L.
Bar-Or, A.
Comi, G.
de Seze, J.
Giovannoni, G.
Hauser, S. L.
Hemmer, B.
Kappos, L.
Lublin, F.
Montalban, X.
Rammohan, K. W.
Selmaj, K.
Traboulsee, A.
Chin, P.
Li, C.
Mairon, N.
Napieralski, J.
Wolinsky, J.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 658 - 659
[9] Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis
Rammohan, Kottil W.
Hartung, Hans-Peter
Arnold, Douglas L.
Bar-Or, Amit
Comi, Giancarlo
de Seze, Jerome
Giovannoni, Gavin
Hauser, Stephen L.
Hemmer, Bernhard
Kappos, Ludwig
Lublin, Fred
Montalban, Xavier
Selmaj, Krzysztof
Traboulsee, Anthony
Chin, Peter
Li, Carrie
Mairon, Nicole
Napieralski, Julie
Wolinsky, Jerry
[J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 31 - 32
[10] Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
Hauser, S. L.
Kappos, L.
Montalban, X.
Craveiro, L.
Hughes, R.
McNamara, J.
Pradhan, A.
Wormser, D.
Koendgen, H.
Wolinsky, J. S.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 317 - 318

← 1 2 3 4 5 →